They’re still at it, Genzyme and Sanofi are still in talks about a takeover by Sanofi and Genzyme is still touting their as-yet-to-be-approved treatment for MS, now openly being called by the name “Lemtrada,” as a $3 billion per year seller.
Campath (Lemtrada) was approved in 2001 for the treatment of lymphocytic leukemia, so for it to be used as a possible treatment for MS, and for Genzyme to be using this as leverage for a higher asking price, is well, in our opinion, shameful considering the price of Campath, aka Lemtrada.
Campath now sells for $30,000 for leukemia treatment. But MS patients need only a fraction of the dose used in cancer patients. At the current price, MS patients could get Campath for $7,000 or so. That’s far less than other MS treatments; just consider Novartis’ new drug Gilenya, priced at $48,000 a year.
So, Genzyme has a dilemma. To get market prices for Campath use in MS, it would have to price the drug differently for each use. But what would stop doctors from using cancer-priced vials rather than MS vials? After all, off-label use is perfectly legal.
What would stop doctors from using the cancer-priced vials rather than the far more expensive MS priced vials?
Could this have anything to do with the name, Lemtrada? A small reformulation tied to a higher price? Rebranding to make us think it isn’t a cheaper drug? We think it’s one of those and we are awaiting more information as it becomes available and will post it up here on our site.
Genzyme’s Lemtrada, sold under the name Campath as a treatment for blood cancer, may have sales of $3 billion to $3.5 billion by 2017 if approved for multiple sclerosis, according to the Cambridge, Massachusetts-based company. Sanofi and Genzyme said they are discussing a “contingent value right,” under which the French drugmaker would make additional payments for regulatory approval of the treatment and the achievement of certain sales thresholds.